Ureaplasma Species Multiple Banded Antigen (MBA) Variation Is Associated with the Severity of Inflammation In vivo and In vitro in Human Placentae. by Sweeney, Emma L et al.
UCLA
UCLA Previously Published Works
Title
Ureaplasma Species Multiple Banded Antigen (MBA) Variation Is Associated with the 
Severity of Inflammation In vivo and In vitro in Human Placentae.
Permalink
https://escholarship.org/uc/item/5tt3s37m
Authors
Sweeney, Emma L
Kallapur, Suhas G
Meawad, Simone
et al.
Publication Date
2017
DOI
10.3389/fcimb.2017.00123
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ORIGINAL RESEARCH
published: 13 April 2017
doi: 10.3389/fcimb.2017.00123
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 1 April 2017 | Volume 7 | Article 123
Edited by:
Margaret E. Bauer,
Indiana University School of Medicine,
USA
Reviewed by:
Azadeh Farzin,
Johns Hopkins University, USA
Bryan Troxell,
North Carolina State University, USA
*Correspondence:
Emma L. Sweeney
el.sweeney@qut.edu.au
Received: 05 January 2017
Accepted: 27 March 2017
Published: 13 April 2017
Citation:
Sweeney EL, Kallapur SG, Meawad S,
Gisslen T, Stephenson S-A, Jobe AH
and Knox CL (2017) Ureaplasma
Species Multiple Banded Antigen
(MBA) Variation Is Associated with the
Severity of Inflammation In vivo and In
vitro in Human Placentae.
Front. Cell. Infect. Microbiol. 7:123.
doi: 10.3389/fcimb.2017.00123
Ureaplasma Species Multiple Banded
Antigen (MBA) Variation Is
Associated with the Severity of
Inflammation In vivo and In vitro in
Human Placentae
Emma L. Sweeney 1*, Suhas G. Kallapur 2, Simone Meawad 1, Tate Gisslen 2, 3,
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Background: The multiple banded antigen (MBA), a surface-exposed lipoprotein,
is a proposed virulence factor of Ureaplasma spp. We previously demonstrated that
the number of Ureaplasma parvum MBA size variants in amniotic fluid was inversely
proportional to the severity of chorioamnionitis in experimentally infected pregnant
sheep. However, the effect of ureaplasma MBA size variation on inflammation in human
pregnancies has not been reported.
Methods: Ureaplasmas isolated from the chorioamnion of pregnant women from
a previous study (n = 42) were speciated/serotyped and MBA size variation was
demonstrated by PCR and western blot. Results were correlated with the severity
of chorioamnionitis and cord blood cytokines. In vitro, THP-1-derived macrophages
were exposed to recombinant-MBA proteins of differing sizes and NF-κB activation and
cytokine responses were determined.
Results: MBA size variation was identified in 21/32 (65.6%) clinical isolates (in 10
clinical isolates MBA size variation was unable to be determined). Any size variation
(increase/decrease) of the MBA (regardless of Ureaplasma species or serovar) was
associated with mild or absent chorioamnionitis (P = 0.023) and lower concentrations of
cord blood cytokines IL-8 (P = 0.04) and G-CSF (P = 0.008). In vitro, recombinant-MBA
variants elicited different cytokine responses and altered expression of NF-κB p65.
Conclusion: This study demonstrates that size variation of the ureaplasma MBA protein
modulates the host immune response in vivo and in vitro.
Keywords: Ureaplasma species, preterm birth, chorioamnionitis, multiple banded antigen (MBA), virulence,
host-microbe Interactions
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INTRODUCTION
The human Ureaplasma species (U. parvum and U. urealyticum)
are prevalent colonizers of the lower genital tract and are known
to colonize up to 80% of women and 50% of men (Cassell et al.,
1993; Volgmann et al., 2005). Although these microorganisms
were traditionally considered to be of low virulence (Volgmann
et al., 2005), more recent evidence suggests that Ureaplasma spp.
may be virulent pathogens of the female upper genital tract. The
Ureaplasma spp. are themicroorganisms isolatedmost frequently
from the amniotic fluid and placentae of women (Hillier et al.,
1988; Knox et al., 1997; Namba et al., 2010; Sweeney et al., 2016),
either in the presence or absence of histological chorioamnionitis
(Sweeney et al., 2016). These microorganisms have been
associated with spontaneous abortion and miscarriage (Naessens
et al., 1987, 1988), preterm birth (Hillier et al., 1988; DiGiulio
et al., 2010), chorioamnionitis (Hillier et al., 1988; Namba et al.,
2010; Sweeney et al., 2016), and preterm premature rupture of
membranes (Jacobsson et al., 2009; DiGiulio et al., 2010). Despite
the fact that Ureaplasma spp. have been isolated from up to
42% of pregnancies that end prematurely (Namba et al., 2010),
the pathogenesis of ureaplasmas is not always clear; particularly
as not all women who are infected with Ureaplasma spp.
experience preterm birth or adverse pregnancy outcomes (Gerber
et al., 2003). Several hypotheses have been proposed to explain
this variation in pathology/outcomes of women infected with
Ureaplasma spp. Researchers have suggested that there may be
“virulent” Ureaplasma species or serovars (Naessens et al., 1988;
Knox and Timms, 1998; De Francesco et al., 2009; Eun et al.,
2013); however, links to a particular species/serovar with a disease
state or adverse outcomes have not been consistent (Zheng et al.,
1992). Others have suggested that virulence may not be limited
to a single species or serovar of ureaplasmas, but instead may be
associated with antigenic variation of the pathogen itself (Zheng
et al., 1992, 1995, 1996; Dando et al., 2012).
The multiple banded antigen (MBA) is a major
surface-exposed (Zheng et al., 1995; Shimizu et al., 2008),
immunodominant antigen of Ureaplasma spp., which activates
NF-κB and the production of cytokines by signaling via Toll-like
receptors (TLRs) 1, 2, and 6 (Shimizu et al., 2008). More recently,
Knox et al. (2010) demonstrated that the number of U. parvum
MBA size variants present within the amniotic fluid of pregnant
sheep (an ovine model of Ureaplasma spp. infection) was
inversely proportional to the severity of inflammation within
the chorioamnion. Sheep infected intraamniotically with the
same strain and dose of U. parvum had divergent inflammatory
responses within their chorioamnion: when >9 MBA size
variants were present, there was little or no inflammation within
the chorioamnion; by contrast, when there were five or fewer
MBA size variants, severe inflammation of the chorioamnion
was observed (Knox et al., 2010). Antigenic variation is a
common feature of a wide range of pathogens; and to date
the mechanisms known to govern Ureaplasma spp. antigenic
variation include: (i) slipped strand mispairing and/or nucleotide
insertions or deletions of simple repeating sequences and (ii)
DNA rearrangements via site-specific recombination (Citti et al.,
2010). While these studies have demonstrated a potential role
for MBA size variation and variability in chorioamnionitis or
pregnancy outcomes; it is currently unclear if MBA size variation
can occur during infection of human placentae and if this
variation results in similar outcomes to what we have previously
reported in an ovine model.
Recently, our research group demonstrated that the
Ureaplasma spp. were the most prevalent microorganisms
(42/535; 7.8%) isolated from late preterm or term placentae
and that their presence (but not the presence of other bacteria)
was associated with chorioamnionitis. However, not all women
whose placentae were infected/colonized with ureaplasmas
had chorioamnionitis: in 15/42 (35.7%), no histological
chorioamnionitis was observed (Sweeney et al., 2016). Using
these same Ureaplasma spp. clinical isolates, we further
investigated the role of MBA virulence in human ureaplasmas.
We hypothesized size variation of the MBA protein (and gene)
would occur in human Ureaplasma spp. clinical isolates, and that
differences in the host immune response (in vivo and in vitro)
would contribute to the severity of inflammation.
MATERIALS AND METHODS
Ethics Statement
The use of human blood and tissues was approved by the
review boards of the Good Samaritan Hospital (approval 09105-
09-067) and Cincinnati Children’s Hospital Medical Center
(approval 2009-0236). All patients gave permission for the
collection of their placentae upon delivery and for their medical
records (demographic data and pregnancy/neonatal outcomes)
to be recorded in a de-identified database, as described in our
previous study (Shepard and Lunceford, 1976; Sweeney et al.,
2016). Chorioamnion inflammation (chorioamnionitis) scores
were performed by a pathologist, blinded to the microbiological
findings, and the severity of chorioamnionitis was graded
according to the guidelines set by Redline et al. (2003). All
subjects gave written informed consent in accordance with
the Declaration of Helsinki for their medical records to be
recorded within a de-identified database. The work within
this study was also submitted to the Human Research Ethics
Committee (HREC) of the Queensland University of Technology
and considered exempt from approval, as patient samples and
data were de-identified prior to shipment/accessing of patient
medical records. The QUT ethics committee also approved
the production of recombinant proteins for use in in vitro
experiments.
Ureaplasma spp. Clinical Isolates
Tissue samples were excised from placentae and snap frozen
prior to transport to Queensland University of Technology
(QUT). At QUT, placental tissue samples were homogenized and
ureaplasmas were cultured and ureaplasma DNA extracted as
previously described (Sweeney et al., 2016). Clinical ureaplasma
isolate cultures were also utilized for extraction of Ureaplasma
proteins as previously described (Dando et al., 2012).
Extraction of DNA from Cultured
Ureaplasmas
Positive ureaplasma cultures from low passage (≤2 passages)
isolates were centrifuged at 4,500× g for 20 min (Allegra XR-15,
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Beckman Coulter, Australia) and nucleic acid was extracted
from the resulting bacterial pellet using the QIAamp mini DNA
extraction kit (Qiagen, Australia). All extracted DNA was stored
at−20◦C until required.
Speciation and Serotyping of Ureaplasma
spp. Clinical Isolates
The upstream conserved region of the Ureaplasma spp. multiple
banded antigen (mba) gene was performed as previously
presented (Sweeney et al., 2016; Accession numbers: KY796009,
KY796010, KY796011, KY796012, KY796013, KY796014,
KY796015, KY796016, KY796017, KY796018, KY796019,
KY796020, KY796021, KY796022, KY796023, KY796024,
KY796025, KY796026, KY796027, KY796028, KY796029,
KY796030, KY796031, KY796032, KY796033, KY796034,
KY796035, KY796036, KY796037, KY796038, KY796039,
KY796040, KY796041, KY796042, KY796043, KY796044,
KY796045, KY796046, KY796047, KY796048, and KY796049)
and the mba gene was used to serotype the U. parvum and U.
urealyticum clinical isolates.
PCR Assays Targeting the Downstream
Repetitive Region of the mba Gene
The downstream repetitive region of U. parvum clinical isolates
was amplified using previously published assays (Knox et al.,
2010; Dando et al., 2012; Robinson et al., 2013). These primers
amplified U. parvum serovars 1 and 6; or serovars 3 and 14 and
revealed size variation within themba gene.
Western Blotting of Ureaplasma spp.
Multiple Banded Antigen (MBA) Protein
Cultures of each clinical isolate and Ureaplasma spp. ATCC
strain were centrifuged at 4,500 × g for 20min. The supernatant
was then discarded and the pellet resuspended in 100µL of
sterile PBS. The suspensions were stored at −20◦C prior to
use. Extracted proteins (30µg) were then used for western blot
analysis, as previously described, to identify size variation in the
MBA protein (Dando et al., 2012).
Cord Blood Cytokine Analysis
Cord blood was collected at the time of delivery from the
umbilical vein using a sterile Viacord collection kit containing
an anticoagulant, and the blood components separated by
centrifugation. Concentrations of cytokines/chemokines within
cord blood plasma were then determined using MILLIPLEX R©
MAP Human Cytokine/Chemokine magnetic bead panel
(Millipore, USA). Concentrations of cytokines/chemokines were
calculated from standard curves using recombinant proteins and
the results were expressed in pg/mL.
Production of Recombinant MBA Proteins
from Ureaplasmas
DNA from ATCC U. parvum serovar 6 and a selection of
U. parvum serovar 6 clinical isolates (#27, #50, and #122
and #334B) were utilized to amplify the mba gene. The mba
gene was selected from these clinical isolates (as they are
representative the large variety of sizes observed within our
U. parvum serovar 6 clinical isolates) in order to determine
if the size of the mba gene (and the expressed MBA protein)
alters the host immune response. All mba genes were selected
from U. parvum serovar 6 isolates that were isolated from
preterm placentae (<37 weeks of gestation). PCR assays were
performed in 50µL reactions, containing: 4µL of DNA template,
50µM dNTPs (ThermoFisher Scientific, Australia), 1.5 mM
MgCl2 (ThermoFisher Scientific), 1µM forward and reverse
PCR primers (forward primer: ACATTAGGAGTTACC; reverse
primer: TTATTTTCTAGCAGC; Sigma Aldrich) 2 units of pfu
polymerase (Promega, Australia) and sterile DNAse/RNAse-free
dH20 (Gibco, Australia). PCR cycling was performed using
the PTC-2000 thermocycler (Bio-Rad, Australia) and cycling
consisted of: denaturation at 95◦C for 5 min, followed by 35
cycles of denaturation at 95◦C for 30 s, primer annealing at 55◦C
for 30 s and extension at 72◦C for 2.5 min. PCR fragments were
then purified using the PureLink PCR amplicon purification kit
(ThermoFisher Scientific) and sequencing was performed (Life
Technologies) to confirm the correctmba gene sequence.
The purifiedmba genes were ligated into the pRSETA plasmid
(kindly provided by Professor Ken Beagley) and transformed
into chemically competent DH5α Escherichia coli. Positive
transformants for each mba gene/protein were then selected
(a minimum of ten per gene/protein) for further analysis, to
confirm the presence of the mba gene within the plasmid.
Plasmids containing the correct insert were then transfected into
BL21 E. coli and stored at−80◦C for future use.
BL21 E. coli strains containing the mba genes were then
used for large-scale protein production. This involved culturing
E. coli strains until logarithmic growth was achieved, followed
by induction of protein expression using isopropyl β-D-
thiogalactoside (IPTG; Bioline, Australia). E. coli were then
allowed to produce the protein of interest for 3 h, before
being collected by centrifugation. The resulting cell pellet was
resuspended in sterile phosphate-buffered saline (PBS). E. coli
were then sonicated prior to protein purification.
MBA proteins were produced with a 6xHis-tag for use
in ion metal chromatography using Talon R© resin (ClonTech,
Australia). MBA proteins were bound to the Talon R© resin for
1 h before a series of washing steps with low concentrations
(10mM) of imidazole to remove any non-specific proteins. After
washing, the protein of interest was eluted from the resin using
500 mM imidazole. Purified rMBA proteins were evaluated by
western blot, using MBA-specific primary antibodies (kindly
provided by Emeritus Dr Patricia Quinn, The Hospital for Sick
Children, Toronto) to demonstrate the recombinant proteins
were of the correct size. All proteins were confirmed to be free of
contaminating LPS; any LPS detected was removed using a high
capacity endotoxin removal kit (Life Technologies, Australia).
In vitro Stimulation of THP-1 Macrophages
Using Recombinant MBA Proteins
THP-1 monocyte cells were grown in Roswell Park Memorial
Institute (RPMI; ThermoFisher Scientific) media containing
10% fetal bovine serum, 1,000 U/mL benzylpenicillin and 0.05
mM β-mercaptoethanol. Cells were seeded into 48-well plates
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(Corning Life Sciences, Australia) at 1 × 105 cells/well and
supplemented with 10 ng/mL phorbol 12-myristate 13-acetate
(PMA; Sigma Aldrich) to induce the differentiation of THP-
1 monocytes to macrophages for 72 h (Park et al., 2007).
After differentiation, the adherent cell monolayer was washed
using sterile PBS and then exposed to 10µg/mL of: ATCC
U. parvum serovar 6 recombinant protein (∼75 kDa), and U.
parvum serovar 6 clinical isolate recombinant MBA proteins
#27 (∼37 kDa), #50 (∼60 kDa), #122 (∼70 kDa), and #334B
(∼75 kDa), suspended in RPMI culture media. Controls included
no recombinant proteins (negative control), macrophages
stimulated with 100 ng/mL Escherichia coli lipopolysaccharide
(E. coli LPS; Sigma Aldrich) and macrophages exposed to 2
× 107 colony forming units (CFU) of live or UV-inactivated
(killed) U. parvum serovar 6. After 24 h, cell culture supernatant
was collected for enzyme-linked immunosorbent assays (ELISA)
for TNF-α, IL-1β IL-6, IL-8, IL-10, and G-CSF (ELISAkit.com,
Australia). THP-1 cells exposed to each treatment group
were also prepared for western blot analysis. Cells from each
experimental group were scraped from the culture vessel
(Sarstedt Pty. Ltd., Australia) and incubated in RIPA buffer
(150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulfate, protease inhibitor cocktail, 50 mM
Tris pH 8.0) at 4◦C for 1 h, to extract the total cell protein.
For SDS-PAGE electrophoresis, 60µg of cell lysate from each
sample was loaded into a gel for subsequent western blotting and
transfer to a nitrocellulose membrane. The membrane was then
stained with Ponceau S dye (Sigma Aldrich), in order to visualize
the protein bands of the correct sizes, before the membrane
was cut and blocked in 5% skim milk solution for 1 h. The
membranes were then probed with human phosphorylated NF-
κB p65 primary antibody (Abcam, Australia) or human β-actin
primary antibody (Abcam) overnight at 4◦C. The membranes
were washed and probed with a rabbit anti-human IgG secondary
antibody (Sigma Aldrich) for 1 h. Protein bands were visualized
using 3′3′-diaminobenzidine (DAB) with metal enhancer (Sigma
Aldrich). The developed membranes were then imaged using
ChemiDoc MP imaging system (Bio-Rad) and densitometry
analysis was performed using ImageJ software (NIH).
Statistical Analysis
All data are presented as the mean value, plus or minus the
standard error of the mean (SEM). Data were analyzed using
analysis of variance (ANOVA) and included adjustments for
multiple comparisons. Statistical significance was accepted as
P < 0.05.
RESULTS
Speciation and Serotyping of Ureaplasma
Clinical Isolates
The upstream conserved portion of the mba gene of 42
Ureaplasma spp. isolates were sequenced (Sweeney et al., 2016).
The majority of these isolates were confirmed to be U. parvum
(36/42; 85.7%) and only 6 (14.3%) U. urealyticum isolates were
identified.
Of the 36 U. parvum clinical isolates, four were unable to be
serotyped by sequencing; however, the remaining isolates were
serotyped asU. parvum serovar 1 (11/32; 34.4%), serovar 3 (9/32;
28.1%), and serovar 6 (12/32; 37.5%). No U. parvum serovar
14 clinical isolates were detected. Of the U. urealyticum clinical
isolates, only two of the six clinical isolates were able to be
serotyped, and these were identified as U. urealyticum serovar 8
and serovar 10.
Ureaplasma Species and Serovars:
Association with Adverse Pregnancy or
Neonatal Outcomes
There were no differences in outcomes for neonates exposed to
U. parvum or U. urealyticum (Table 1).
We also compared the outcomes of mothers and their infants
exposed to the most common serovars within our study: U.
parvum serovars 1, 3, and 6. Women whose placentae were
infected with U. parvum serovar 3 (n = 9) were younger (21.4
± 0.9 years) than women in whom U. parvum serovars 1 (n =
11) or 6 (n = 12) were identified (25.6 ± 1.3 and 26.0 ± 1.4
years, respectively; P = 0.024) (Table 2). There were no other
differences between these three groups of women, nor were there
any differences in the incidence of adverse neonatal outcomes,
including the prevalence of histological chorioamnionitis.
PCR and Western Blot Targeting the MBA
Protein and mba Gene
The MBA protein and mba gene of ureaplasma clinical isolates
were compared to American Type Culture Collection (ATCC)
strain controls (serovar 1, 3, 6, 8, and 10, which served as
positive controls for the size/expression of the MBA/mba).
Numerous MBA/mba size variants were detected within low-
passage (≤passage 2) clinical isolates (Figure 1). For some
ureaplasma clinical isolates, there was no identifiable MBA/mba
size variation, i.e., the MBA protein andmba gene were the same
size as the antigens/genes of the ATCC strain serovars (Serovar
1 isolates: 1A, 1B, 262T, 507; Serovar 3 isolates: 33A, 33B, 322T,
325; and Serovar 6 isolates: 334A, 334B, 364A); for other clinical
isolates, variation in the size of their MBA protein and mba
gene band(s) were observed. These clinical isolates demonstrated
either a “single MBA/mba size variant,” which was considered
to be an individual protein/gene band that differed in size when
compared to the corresponding ATCC strain controls (Serovar
1 isolates: 43, 301, 473T, 483T, 498A, 498B; Serovar 3 isolates:
44A, 44B, 314T, 365, 435; Serovar 6 isolates: 27, 50, 55B, 122,
and 310T; Serovar 8 isolate: 8; and Serovar 10 isolate 300); or
in some cases, “multiple MBA/mba variant” bands were seen,
where more than one MBA/mba band was visualized by PCR
or western blot (Serovar 1 isolates: 290T; Serovar 6 isolates: 182,
429) (Figure 1). We did not see any difference in the propensity
for these Ureaplasma isolates to vary the size of their MBA/mba,
according to the species or serovar identified (Table 3).
For some clinical isolates, n = 2 U. parvum serovar 6 isolates
and n= 8U. urealyticum isolates the MBA protein andmba gene
were not detected or visualized. Therefore, we were unable to
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TABLE 1 | Maternal and neonatal demographic and outcome data for women whose placentae were infected with U. parvum or U. urealyticum.
U. parvum (n = 36) U. urealyticum (n = 6) Significancea
MATERNAL
Maternal age (years; mean, range) 24.7 ± 0.8 (17–32) 22.8 ± 2.0 (19–32) 0.046
Gravida (mean, range) 1.9 ± 0.2 (1–5) 3.2 ± 0.3 (2–4) NSb
Parity (mean, range) 1.7 ± 0.2 (1–4) 2.3 ± 0.4 (1–4) NS
At least one sign/symptom of infectionc 4/36 (11.1%) 1/6 (16.7%) NS
Preterm premature rupture of membranes (pPROM) 11/36 (30.6%) 4/6 (66.7%) NS
ETHNICITY
Caucasian 22/36 (61.1%) 1/6 (16.7%) NS
African-American 12/36 (33.3%) 5/6 (83.3%) NS
Asian 0/36 (0.0%) 0/6 (0.0%) NS
More than one race 2/36 (5.6%) 0/6 (0.0%) NS
FETAL
Gestational age at delivery (weeks; mean, range) 35.9 ± 0.41 (32–41) 34.7 ± 0.61 (32–36) NS
Birth weight (grams; mean, range) 2,550 ± 102.47 (1,380–3,873) 2674.17 ± 148.17 (2,290–3,330) NS
Placental weight (grams; mean, range) 456.0 ± 22.9 (260–710.7) 400.4 ± 14.3 (374–461) NS
Histologic Chorioamnionitisd 22/36 (61.1%) 5/6 (83.3%) NS
Maternal Stage 1.5 ± 0.1 (1–3) 1.6 ± 0.2 (1–2) NS
Fetal Stage 2.0 ± 0.2 (1–3) 3.0 ± 0.04 NS
Continuous positive airway pressure (CPAP) 6/36 (16.7%) 2/6 (33.3%) NS
Required oxygen support for > 6 h 4/36 (11.1%) 3/6 (50.0%) NS
Diagnosed with respiratory distress syndrome (RDS) 5/36 (13.9%) 2/6 (33.3%) NS
Length of stay in hospital (days; mean, range) 6 ± 1.2 (1–28) 5.5 ± 1.7 (2–13) NS
aStatistical significance determined by analysis of variance (ANOVA).
bNS—not statistically significant.
cDefined as maternal temperature of >38◦C, uterine or abdominal tenderness, foul-smelling vaginal discharge, maternal tachycardia (heart rate, >120 beats/min), or fetal tachycardia
(heart rate, >160 beats/min).
dAssessed using tissue sections from each placenta according to criteria set out in Redline et al. (2003). Maternal and fetal grades of chorioamnionitis are listed as median and range.
determine if MBA/mba size variation occurred in these clinical
isolates.
MBA/mba Size Variation was Associated
with Altered Immune Responses In vivo
The maternal demographic data of ureaplasma-infected women
in which MBA/mba variation was identified was compared to
those women in whom no MBA/mba size variation was seen.
No differences were observed (data not shown). However, a
major finding of this study was that Ureaplasma spp. MBA/mba
size variation was associated with differences in the incidence
of histological chorioamnionitis as graded by a US pathologist
(Figure 2A). Cord blood cytokines from women in which no
microorganisms were detected (by culture and PCR) were
compared to the cord blood cytokine profiles from women
whose placentae were found to be infected with Ureaplasma
spp. Placentae which harbored ureaplasmas with no MBA/mba
size variation demonstrated a higher prevalence of histological
chorioamnionitis (9/11; 81.8%), when compared to placentae
in which the ureaplasmas present expressed either a single or
multiple MBA/mba size variant(s) (10/21; 47.6% p = 0.03). No
differences in the severity of inflammation within the maternal
and fetal sides of these membranes were observed (Figure 2A).
There were no other differences in pregnancy or neonatal
outcomes associated with ureaplasma MBA/mba size variation.
Cord blood samples collected at the time of delivery were also
tested for inflammatory markers (cytokines, chemokines, and
growth factors including IL-1β, IL-6, IL-8, MCP-1, and G-CSF).
In vivo, when ureaplasma MBA/mba size variation occurred
within infected placentae, lower concentrations of IL-8 (67.7
pg/mL) andG-CSF (128.7 pg/mL) were detected, when compared
to the concentrations of these same cytokines in placentae
which were infected with Ureaplasma spp. but demonstrated
no MBA/mba size variation (IL-8: 137.7 pg/mL, G-CSF: 277.0
pg/mL; P = 0.044, P = 0.008, respectively; Figure 2B).
In contrast, levels of MCP-1 in cord blood were significantly
elevated when ureaplasmas which demonstrated MBA/mba size
variation were isolated from placentae, when compared to the
cord blood collected from those placentae which were infected
with ureaplasmas that showed no variation in the size of their
MBA/mba (P = 0.048).
MBA Size Variation was Also Associated
with Altered Immune Responses In vitro
To further investigate the role of MBA size variation and
the host response, we challenged differentiated human THP-
1 (macrophages) with recombinant MBA proteins of differing
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TABLE 2 | Maternal and neonatal demographic/outcome data for women whose placentae were infected with U. parvum serovars 1, 3, or 6.
Serovar 1 (n = 11) Serovar 3 (n = 9) Serovar 6 (n = 12) Significancea
MATERNAL
Maternal age (years; mean, range) 25.6 ± 1.3 (18–32) 21.4 ± 0.9 (17–26) 26.0 ± 1.4 (19–32) 0.024
Gravida (mean, range) 2.0 ± 0.3 (1–4) 1.7 ± 0.4 (1–4) 1.9 ± 0.4 (1–5) NSb
Parity (mean, range) 1.9 ± 0.3 (1–4) 1.4 ± 0.2 (1–2) 1.8 ± 0.3 (1–4) NS
At least one sign/symptom of infectionc 2/11 (18.2%) 1/9 (11.1%) 0/12 (0.0%) NS
Preterm premature rupture of membranes (pPROM) 2/11 (18.2%) 3/9 (33.3%) 3/12 (25.0%) NS
ETHNICITY
Caucasian 9/11 (81.8%) 7/9 (77.8%) 6/12 (50.0%) NS
African-American 2/11 (18.2%) 2/9 (22.2%) 5/12 (41.7%) NS
Asian 0/11 (0.0%) 0/9 (0.0%) 0/12 (0.0%) NS
More than one race 0/11 (0.0%) 0/9 (0.0%) 1/12 (8.3%) NS
FETAL
Gestational age at delivery (weeks; mean, range) 36.5 ± 0.9 (33–41) 35.9 ± 0.7 (33–39) 35.3 ± 0.7 (32–40) NS
Birth weight (grams; mean, range) 1,975 ± 174.1 (1,975–3,873) 2650.7 ± 219.5 (1,525–3,855) 2370.8 ± 186.63 (1,380–3,825) NS
Placental weight (grams; mean, range) 524.2 ± 38.7 (270–635) 482.4 ± 48.5 (279–710.7) 395.8 ± 31.7 (260–655) NS
Histologic Chorioamnionitisd 7/11 (63.6%) 5/9 (55.5%) 7/12 (58.3%) NS
Maternal Stage 1.6 ± 0.2 (1–2) 1.25 ± 0.1 (1–2) 1.6 ± 0.3 (1–3) NS
Fetal Stage 2.5 ± 0.2 (2–3) 2 ± 0.3 (1–3) 1.7 ± 0.3 (1–3) NS
Continuous positive airway pressure (CPAP) 1/10 (10%) 2/9 (22.2%) 3/12 (25.0%) NS
Required oxygen support for > 6 h 1/10 (10%) 2/9 (22.2%) 2/12 (16.7%) NS
Diagnosed with respiratory distress syndrome (RDS) 1/10 (10%) 2/9 (22.2%) 2/12 (16.7%) NS
Length of stay in hospital (days; mean, range) 7.6 ± 2.7 (1–28) 5.0 ± 2.1 (1–16) 6.9 ± 1.8 (2–17) NS
aStatistical significance determined by analysis of variance (ANOVA).
bNS—not statistically significant.
cDefined as maternal temperature of >38◦C, uterine or abdominal tenderness, foul-smelling vaginal discharge, maternal tachycardia (heart rate, >120 beats/min), or fetal tachycardia
(heart rate, >160 beats/min).
dAssessed using tissue sections from each placenta according to criteria set out in Redline et al. (2003). Maternal and fetal grades of chorioamnionitis are listed as median and range.
sizes, using Escherichia coli lipopolysaccharide (LPS) as a positive
control. These recombinant MBA proteins were produced from
U. parvum serovar 6 ATCC strain (control), and from U. parvum
serovar 6 clinical isolates (isolates: #27, #50, #122, and #334B; see
Figure 1).
When THP-1 macrophages were exposed to the E. coli
LPS control, robust immune responses were detected for the
cytokines TNF-α, IL-1β, IL-8, and G-CSF. In vitro, the ATCC
U. parvum recombinant MBA (rMBA;∼75 kDa) protein elicited
the strongest immune response of all rMBA proteins tested;
and stimulated the production of TNF-α, IL-1β, IL-8, and G-
CSF (Figure 3). Similarly, the equivalent size rMBA protein of
isolate #334B (∼75 kDa) elicited similar immune responses.
In contrast, recombinant proteins that were smaller in size
(compared to ATCC U. parvum serovar 6 and the rMBA #334B)
elicited diminished cytokine responses. The rMBA #50 protein
(∼60 kDa) elicited lower concentrations of TNF-α (36.6 ± 25.9
pg/mL; P = 0.024) and G-CSF (5.3 ± 1.3 pg/mL; P = 0.044),
when compared to the concentrations seen in response to the
rMBA of ATCC U. parvum serovar 6.; while the rMBA #122
(∼70 kDa) elicited lower levels of TNF-α (35.2 ± 1.1 pg/mL;
P = 0.020), IL-1β (14.9 ± 2.1 pg/mL; P = 0.045), and G-
CSF (5.3 ± 1.7 pg/mL; P = 0.039). The smallest rMBA #27
(∼37 kDa) elicited the production of cytokines at similar levels
to that of our negative (no treatment) controls (TNF-α: P =
0.002, IL-1β: P = 0.033, G-CSF: P < 0.001; Figure 3), with the
exception of IL-8. Interestingly, regardless of the challenge (LPS,
U. parvum controls, no treatment and rMBA proteins) there
were no differences in the concentrations of IL-8. Similarly, no
significant differences were seen in IL-6 and IL-10 cytokine levels
in cell culture supernatants (data not shown).
Since altered cytokine responses were observed when
macrophages were exposed to different rMBA protein size
variants, we further investigated the activation/expression of
NF-κB p65, the protein complex that controls transcription of
DNA and cytokine production, in cells exposed to the different
sized rMBA proteins. Western blot and densitometry analyses
revealed that the expression of NF-κB was highest for cell lysates
exposed to LPS, ATCC U. parvum serovar 6 and rMBA #334B
(Figures 4A,B). By contrast, diminished expression of NF-κB p65
was observed in cell lysates after exposure to rMBAs #27 and
#122, relative to host (β-actin) controls (Figure 4).
DISCUSSION
The pathogenic role of Ureaplasma spp. remains controversial,
as ureaplasma infection within placentae is not always associated
with inflammation and adverse pregnancy outcomes (Gerber
et al., 2003). Furthermore, the host immune response which
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FIGURE 1 | Variation of the MBA protein and mba gene was detected by western blot and PCR. MBA/mba size variation was characterized by comparing
the protein and PCR amplicons to the ATCC strain serovar control and a molecular weight marker bands. Images were cropped and displayed at their correct
molecular weight and sorted according to their serovar. M, protein marker; 10B, 10B media control; N, negative control; S, serovar 1, 3, 6, 8, 10—ATCC positive
controls; A/B, twin pregnancies; T, term pregnancy (where all others are late preterm: 32–36 weeks of gestation). (A) serovar 1. (B) serovar 3. (C) serovar 6. (D)
serovar 8. (E) serovar 10.
TABLE 3 | MBA size variation in U. parvum serovars.
Serovar 1 (n = 11) Serovar 3 (n = 9) Serovar 6 (n = 10)a Significance
No MBA size variants 4/11 (36.4%) 4/9 (44.4%) 3/10 (30.0%) NS
Single MBA size variant 6/11 (54.5%) 5/9 (55.6%) 5/10 (50.0%) NS
Multiple MBA size variants 1/11 (9.1%) 0/9 (0.0%) 2/10 (20.0%) NS
We identified no differences in the ability of U. parvum serovars to vary the size of their MBA/mba.
aNo MBA was detected for 2 of the U. parvum serovar 6 clinical isolates (n = 12 in total).
influences the development of pathology/disease has not been
well-studied during Ureaplasma spp. infections. A previous
study by our group demonstrated that Ureaplasma spp. were
the most prevalent bacteria detected within the chorioamnion
of women (7.8%) who delivered late preterm or at term, but
not all women infected with ureaplasmas developed histological
chorioamnionitis (Sweeney et al., 2016). In this current study,
we investigated the factors previously implicated in adverse
pregnancy outcomes and inflammation during Ureaplasma spp.
infection.
Similar to our previous study, in which U. parvum was
the most frequently isolated bacterial species (86%) (Sweeney
et al., 2016), in this current study we identified that U. parvum
serovars 1, 3, and 6 were the most common ureaplasma
serovars detected within infected placentae. However, we found
that regardless of the Ureaplasma species or serovar isolated
within the chorioamnion, the incidence of chorioamnionitis
and other adverse pregnancy/neonatal outcomes did not differ
(Tables 1, 2). Previous studies have suggested the existence
of “virulent” Ureaplasma species or serovars (Naessens et al.,
1988; Knox and Timms, 1998; Knox et al., 2003; Dando
et al., 2012; Sweeney et al., 2016); however, ureaplasmas
may not be intrinsically “virulent” or “avirulent,” rather, that
other factors may instead contribute to adverse outcomes
during ureaplasma infections. Furthermore, our findings are
consistent with previous studies that have shown Ureaplasma
spp. to be associated with chorioamnionitis (Hillier et al., 1988;
Cassell et al., 1993; Namba et al., 2010), but ureaplasmas
may also be detected within the placentae of women with no
evidence of chorioamnionitis and the pregnancy may continue
until term delivery, as was also reported by Gerber et al.
(2003).
The most significant finding of this study was thatUreaplasma
spp. isolated from the placentae of human pregnancies
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FIGURE 2 | MBA/mba size variation was associated with the incidence and severity of histological chorioamnionitis. (A) Histological chorioamnionitis was
more prevalent in placentae infected with Ureaplasma spp. that did not vary their MBA/mba, when compared to placentae infected with Ureaplasma spp. that
expressed a single or multiple MBA/mba size variants (B) MBA/mba size variation was also associated with altered levels of cord blood cytokines in vivo. *P < 0.05,
**P < 0.01.
demonstrated differences in the size of their MBA protein and
mba gene. Some of the clinical ureaplasma isolates obtained
from chorioamnion tissue expressed no MBA size variation (and
their proteins were the same size as our ATCC strain controls),
while other clinical isolates expressed a single or multiple MBA
size variants (as evidenced by single or multiple MBA bands
which differed in size, when compared to the control serovar
ATCC strains). While we saw no differences in the propensity
of the different Ureaplasma species or serovars to vary the size
of their MBA/mba (Table 3), our study demonstrated that a
lack of MBA/mba size variation in vivo was associated with a
significantly higher incidence of histological chorioamnionitis
(Figure 2A) and elevated levels of the cord blood cytokines IL-
8 and G-CSF (Figure 2B). By contrast, when MBA/mba size
variation occurred, this was associated with a significant (∼30%)
reduction in the incidence of histological chorioamnionitis and
significantly lower levels of the cord blood cytokines IL-8 and
G-CSF (P = 0.04 and P = 0.008; Figure 2B).
Previous studies have indicated that the severity of
chorioamnionitis varied, depending on the numbers of
Ureaplasma spp. present within placental tissue (Jacobsson
et al., 2009; Kasper et al., 2010; Kacerovsky et al., 2011); however,
within our previous study of n= 535 placentae we did not find an
association between the numbers of ureaplasmas present within
the chorioamnion and the severity of chorioamnionitis (Sweeney
et al., 2016). Instead, the results of this current study support the
proposal that the severity of inflammation is associated with the
degree of MBA/mba size variation.
We further investigated the role of MBA/mba size variation
using an in vitro cell culture model: differentiated THP-1
(macrophage) cells were stimulated with rMBA U. parvum
serovar 6 proteins of differing sizes. Of the rMBA proteins tested,
the ATCC U. parvum serovar 6 protein elicited the greatest
cytokine response, followed closely by the rMBA protein #334B,
which was equivalent in size to that of the ATCC strain. In
contrast, rMBA serovar 6 proteins that differed in size to the
ATCC U. parvum serovar 6 strain and #334B proteins elicited
lower concentrations of cytokines TNF-α, IL-1β, and G-CSF.
For the rMBAs #27 and #122 significantly lower concentrations
of IL-1β were also elicited when these proteins were exposed
to THP-1 cells (Figures 3A–D). However, no differences were
observed in the concentrations of IL-6 or IL-10 in the cell
culture supernatant (data not shown). Of great interest, the
smallest recombinantMBA protein #27 elicitedminimal cytokine
production and these concentrations of cytokines were similar
to those in response to the negative (no treatment) control,
indicating that the macrophages within this study may be
unable to recognize this protein. These findings were confirmed
by the results of densitometry analyses of NF-κB p65, the
protein complex that controls transcription of DNA and cytokine
production (Rahman and McFadden, 2011). Altered expression
of NF-κB p65 was demonstrated in cell lysates exposed to rMBA
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FIGURE 3 | Recombinant MBA proteins of differing sizes elicit varying immune responses in THP-1 macrophages in vitro. Assays were conducted on cell
culture supernatant taken from differentiated THP-1 (macrophages) exposed to recombinant proteins, or controls, for 24 h. ELISA assays for (A) TNF-a, (B) IL-lB, (C)
IL-8, and (D) G-CSF expressed in picograms per milliliter of culture supernatant. *P < 0.05, **P < 0.01, ***P < 0.001.
proteins that were different in size, when compared to ATCC U.
parvum serovar 6 and #334B recombinant proteins. NF-κB p65
expression was decreased for recombinant proteins #27 and #122
(Figures 4A,B), and this corresponded directly to the diminished
cytokine levels seen in vitro (Figure 3).
It was first reported in 2008 that the Ureaplasma spp.
surface-exposed lipoproteins, predominantly the MBA, induced
an inflammatory response that resulted in the induction of NF-κB
though TLRs 1, 2, and 6; and this study further proposed that size
variation of the MBA may affect the stimulatory activity of the
ureaplasma MBA and its ability to interact with TLRs (Shimizu
et al., 2008). Others have reported the cytokine responses elicited
when: (i) adult humanmonocytes and term and preterm neonatal
cord bloodwere exposed to low (103 color changing units [CCU])
or high doses (106 CCU) of U. parvum serovars 3 (Manimtim
et al., 2001), (ii) human monocytes (THP-1 cells) were treated
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FIGURE 4 | NF -KB p65 expression alters upon exposure to different
size recombinant MBA proteins in vitro. (A) NF-KB p 65 expression is
altered upon exposure to recombinant MBA proteins of differing sizes, when
normalized to host (β-actin) controls. (B) Densitometry analyses from n = 3
experiments, performed in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001.
with heat-killed U. urealyticum (Li et al., 2000), (iii) THP-1
macrophages were exposed to surface lipoproteins ofUreaplasma
urealyticum (Peltier et al., 2007), and (iv) human amniotic
epithelial cells were exposed to Ureaplasma spp. serovars 2, 3,
and 14 (1 × 108 bacteria/mL) (Triantafilou et al., 2013). In
each of these in vitro experiments, the production of TNF-α
was elevated in response to the ureaplasmas/antigens presented.
However, the production of other cytokines (IL-1β, IL-8, IL-6,
and IL-10) varied depending on the cell type, the bacterial or
antigenic load, and the presence of LPS or steroids. A major
strength of our current study was the correlation of immune
responses in differentiated THP-1 (macrophages) to the same
ureaplasma serovar (live or UV-inactivated U. parvum serovar 6)
and rMBA proteins of differing sizes that were synthesized
from low-passage U. parvum serovar 6 clinical isolates originally
isolated from human placentae. These experiments confirm that
rMBA proteins of differing sizes elicit varying concentrations of
cytokines (IL-1β, IL-8, MCP-1, and G-CSF), depending on the
size of the MBA antigens expressed by the ureaplasmas in vitro
or in vivo.
Antigenic variation is an important mechanism used by
microorganisms to mediate their interaction with the host and/or
environment and this variation is thought to be an essential
strategy employed by microorganisms to assist in pathogen
survival, particularly in the presence of a host immune response
(Citti et al., 2010). Antigen variation is not a unique trait of
Ureaplasma spp., many microbes possess the ability to vary
their surface exposed antigens (Citti et al., 2010; Foley, 2015);
however, MBA/mba size variation has been reported previously
in a sheep model of intraamniotic ureaplasma infection (Knox
et al., 2010; Dando et al., 2012; Robinson et al., 2013). To the
best of our knowledge, this current study is the first to identify
variation of the Ureaplasma spp. MBA/mba in human placentae,
and to demonstrate that this variation is associated with the
incidence and severity of chorioamnionitis during pregnancy.
Furthermore, this study is also the first to demonstrate that levels
of cord blood cytokines differ when the placenta of pregnant
women infected with ureaplasmas express different MBA/mba
size variants.
Previous studies have investigated the role of size variation
of the MBA/mba. Initial studies demonstrated the ability
of Ureaplasma spp. isolated from neonates to vary their
surface-exposedMBA/mba (Zheng et al., 1992) and that variation
of the MBA/mba correlated with the number of repeating units
in the downstream (surface-exposed) portion of the protein
and gene (Zheng et al., 1995). These authors suggested that
further knowledge of MBA size variation “would be requisite to
understanding the role that these antigens and their associated
size variation may play in the success or failure of these
organisms as pathogens” (Zheng et al., 1995). Further studies
by this same group utilized antibody-reactive peptide scanning
and showed that differences in the numbers of repeating units
within the MBA were associated with altered recognition of
the MBA by sera which contained anti-ureaplasma antibodies
(Zheng et al., 1996). In this previous study an interesting
trend was observed; the ability of the monoclonal antibodies
to bind to the MBA increased with the number of repeating
units present (Zheng et al., 1996). This finding correlates with
our data, which demonstrated that MBA size variation resulted
in altered immune responses, both in vivo and in vitro and
suggests that MBA size variation may be a mechanism by
which ureaplasmas can evade either innate or adaptive immune
responses.
Zimmerman et al. (2009, 2013) in in vitro experiments
demonstrated inversion events that occurred between the mba
and other regions with the genome of U. parvum serovars 3.
These events were confirmed on both the genomic and protein
level. They concluded that these DNA inversion events are
dynamic and result in the high-frequency, broad spectrum,
antigenic variation of these pathogens. While in these studies,
DNA inversion events were not characterized in vivo, studies
by Dando et al. (2012) identified ovine anti-ureaplasma IgG
antibodies within maternal and fetal serum that were collected
after sheep were infected intraamniotically with the same U.
parvum low passage clinical isolate. This study revealed that
the anti-ureaplasmal antibodies from these animals reacted with
more than one ureaplasma MBA size variant, and that the IgG
reactivity differed between animals (Dando et al., 2012). This
study confirmed that MBA/mba size variation occurred in vivo
and we and others (Zheng et al., 1992, 1995, 1996; Monecke
et al., 2003; Zimmerman et al., 2009, 2011, 2013) propose that
this variation is an important immune evasion mechanism for
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Ureaplasma spp. Similar antigenic variation leading to immune
evasion has been noted in several other well-studied organisms,
including Plasmodium falciparum, Mycoplasma pulmonis, and
the human immunodeficiency virus (Lipsitch and O’Hagan,
2007; Citti et al., 2010). Further studies are required to
understand the immune pressures which may trigger MBA/mba
size variation in vivo and in vitro and to determine how these
changes of the organism facilitates immune evasion.
In summary, this is the first study to demonstrate MBA/mba
size variation within ureaplasmas isolated from the human
chorioamnion. Our data suggest that Ureaplasma species or
serovars are not intrinsically “virulent” or “avirulent,” but
instead that variation of the ureaplasma MBA protein may
play an important role in modulating the immune response:
when MBA/mba size variation occurred in vivo there was
a decrease in the incidence of chorioamnionitis and lower
levels of the cord blood cytokines IL-8 and G-CSF. This
hypothesis was also supported by our in vitro findings that
recombinant MBA proteins of different sizes elicited altered
cytokine responses and augmented expression of NF-κB p65
in macrophages. While variation in the size of the MBA/mba
did not always result in an abolished immune response in
vitro and in vivo, the responses to these variants were often
diminished and this is consistent with an immune evasion
event. The ability of these microorganisms to alter/modulate
the host immune response may be a contributing factor to
the virulence of the Ureaplasma spp. in establishing chronic,
asymptomatic infections in utero, and highlights the need
for future studies of these microorganisms as underestimated
pathogens of pregnancy.
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